30 June 2017

The Honorable Senator Ron Wyden 221 Dirksen Senate Office Bldg. Washington, D.C., 20510

Dear Senator Wyden:

We write regarding your joint letter of June 23, 2017 with Senator Hatch and Representatives Brady and Neal to President Trump, in which you urge the President to address concerns regarding India's intellectual property rights policies.

In that letter, you specifically mention pharmaceutical patents amidst discussion of "India's weak standards," and cite a 2014 U.S. International Trade Commission report calling for India's standards for IP protection to be made comparable to U.S. and Western European levels. We are surprised and dismayed that you are pressuring India to grant additional patents on drugs and vaccines.

In 2015, the income per capita was \$1,590 USD in India, and \$55,980 — more than 35 times higher — in the United States. A country with as much poverty as India should not enforce patents on drugs and vaccines the same way as high-income industrialized countries. Moreover, India is the most important source of low cost drugs in the world, and a critically important source of affordable generic products in many developed and developing countries.

The practical effect of the type of trade pressures you advocate is to enhance the monopoly power and raise the prices of new drugs for cancer and many other diseases. This is appalling.

Sincerely,

Ann Pickar, Founder, Portland Area Global AIDS Coalition, Portland, Oregon, Chair, Africa Connections, First Unitarian Church of Portland, Oregon, USA Christa Sprinkle, Portland, Oregon, USA Dashiell Love, Newport, Oregon

All India Drug Action Network (AIDAN), India Aparajita Das, Faculty of Iaw, India Dr. Mira Shiva, New Delhi, India Dr. P.R.K. Murti, Retired Professor, University of Hyderabad, Hyderabad, India Dr Gopal Dabade, President, Drug Action Forum Karnataka, Dharwad, India Karin kotian, Mumbai, India Priyank Kapadia, Mumbai Maharashtra India Swaraj Paul Barooah, SpicyIP, Bangalore, India T G Agitha, Professor, IUCIPRS, India Global Health Justice Partnership, Initiative of Yale Law School & Yale School of Public Health Knowledge Ecology International (KEI) Public Citizen Social Security Works The Other 98% Universities Allied for Essential Medicines (UAEM)

Dean Baker, co-founder and director, CEPR, Washington, DC, USA George Carter, Founder/Director, Foundation for Integrative AIDS Research, Brooklyn, NY Hilary McQuie, Director of US Policy, Health Global Access Project, Washington DC Manon Ress, Union for Affordable Cancer Treatment (UACT) Mark S. King, Person Living with AIDS, Baltimore, MD Theo Smart, ACT UP, New York, NY

Amy Kapczynski, Professor of Law at Yale Law School, New Haven, CT Gregg Gonsalves, Assistant Professor, Yale School of Public Health, New Haven, CT Matthew Flynn, Georgia Southern University, Statesboro, GA Nicole Hassoun, Fellow, Hope & Optimism Project, Cornell University, Ithaca, New York Shobita Parthasarathy, Associate Professor, Ford School of Public Policy, University of Michigan, Ann Arbor, MI

Daniel White, New York, NY Holly Horne, Flushing NY USA John James, Philadelphia, PA John Weir, Brooklyn, NY, USA Michael Luciano, Charleston, SC USA Patrice Parker, Anchorage, Alaska, US Richard Jackman, Bellingham, WA USA Saundra Johnson, Minneapolis, MN 55406

Ante Wessels, Vrijschrift Foundation, Amsterdam, The Netherlands David Banta, Professor Emeritus, Maastricht University, Amsterdam, the Netherlands

Joan Rovira, Professor Emeritus, University of Barcelona, Barcelona, Spain Rob Camp, Barcelona/Catalunya/Spain

Dr Dzintars Gotham, London, UK

Fifa Rahman, PhD Student, Intellectual Property, University of Leeds, Leeds, United Kingdom Michael I Hutnik, Managing Director, Multi-dimensional Re:Align, Guildford, UK Rachel Logan, Matrix Chambers, London, United Kingdom